HPM Department News

Jarlenski revisits "Arguments, Evidence, and Abortion Policy" on public health podcast

PUBLIC HEALTH POST - HPM’s Marian Jarlenski discusses her article "Arguments, Evidence, and Abortion Policy" during the Public Health Post's podcast hosted by Boston University's School of Public Health. 

Chancellor Gallagher shares his outrage, grief, and solidarity

In a letter to the community, Chancellor Gallagher shares his outrage, grief, and anger. He challenges us all to demonstrate solidarity by standing with Pitt’s African American students, faculty, staff, and alumni in a shared commitment to realizing meaningful change. "How many times must we witness these blatant examples of injustice, hatred, brutality, and discrimination before we resolve to change things?"  We must plot a path forward.  ... 

Papalia receives PhD in Kinesiology from Penn State

Congratulations to Zack Papalia who received his PhD in Kinesiology at the 2019 winter commencement at Penn State University. Papalia earned his Master of Public Health from the Department of Health Policy and Management in 2012.  

Roberts on agent-based modeling and finding the right balance to easing restrictions

CLEVELAND.COM - Pitt Public Health researchers are monitoring the coronavirus through FRED , which is short for a Framework for Reconstructing Epidemiological Dynamics. The agent-based modeling system uses population data to represent each person in a geographic region. The FRED team is currently researching scenarios for easing social-distancing measures and reopening. The goal is to identify strategies that could be most effective.  

Gellad comments on the therapies being developed to combat the new coronavirus

THE OREGONIAN - Hundreds of COVID-19 treatment drugs are being studied and some experts say scientists should cast a wide net. “I don’t think we want to rule anything out because it sounds out of the ordinary,” said HPM’s Walid Gellad, director of Pitt’s Center for Pharmaceutical Policy and Prescribing.  

Gellad on how the info war over chloroquine has slowed Covid-19 science

WIRED – No one really knows if the malarial drug helps fight Covid-19, and an information war is hindering the struggle to find out. Unorthodox research methods and a seeming rush to publication, or even prepublication, is muddiing the situation. Walid Gellad, HPM faculty and head of Pitt's Center for Pharmaceutical Policy and Prescribing, says a French study was low quality in terms of trial design and evidence of whether it works or not.  

Gellad concerned that government researchers changed metric to measure coronavirus drug remdesivir during clinical trial

WASHINGTON POST – “It raises a lot of flags, and it requires a lot of answers,” said HPM’s Walid F. Gellad who also serves as head of Pitt's Center for Pharmaceutical Policy and Prescribing, “especially when people start saying it’s become the standard of care, and all we saw was a news release in a trial with an outcome that was changed two weeks ago. It really is striking.”  

‘Will my county reopen soon?’ Roberts describes factors going into ‘red’ to ‘yellow’ decision

WTAE - HPM’s Mark Roberts said, “We don’t really know how many people have been sick, or have gotten infected and not gotten sick. Since there can be asymptomatic carriers, we need to ramp up testing to determine which counties can reopen. He’ll be looking closely at states that have eased stay-at-home restrictions to see what impact, if any, a limited reopening has.  

Angus says disorganized research slows discovery of COVID-19 treatments

NPR - Pitt Med's Derek Angus (BCHS '92) says the problem is that our system rewards tribalism, with insufficient motivation for effective collaboration. He's leading a fast-track remap trial for COVID-19, part of an international effort involving hundreds of investigators. He has lots of opinions about which drugs might work best, but he'd rather focus on a trial design that can be as modular as possible and let as many people in as possible.  

Gellad agrees that we’re repeating one of the worst mistakes of the Ebola outbreak in the hunt for a coronavirus cure

BUSINESS INSIDER - By the time global health groups agreed on a testing strategy for Ebola, the epidemic had waned and there weren’t enough people to test. HPM’s Walid Gellad, director of Pitt’s Center for Pharmaceutical Policy and Prescribing, said it’s a legitimate worry that the torrent of studies will compete for the same pool of patients, making it harder to find enough people to test all the drugs.  

HPM students take home second place at Penn State University Health Care Management Case Competition

Nolan Cianci (HPM ’21), Mara Menk (HPM ’22), and Devin Strynkowski (HPM ’21), coached by MPH program director and HPM faculty member Elizabeth Van Nostrand, placed 2 nd in the Penn State University Health Care Management Case Competition  

Roberts on a decision for re-opening economy

WTAE - HPM’s Mark Roberts said a drop in coronavirus cases means that people are following social distancing guidelines. He thinks President Trump's plan is “reasonable,” but he added, “What we need to do is understand the impact of the decisions we’re making on the disease and on the economy.”  

Angus says the search for coronavirus treatments is jumbled

CNN – The scramble for successful treatments is disjointed and chaotic, according to Pitt Med's Derek Angus (BCHS '92). There are two million people who already have this disease. If even one in 10 has been able to participate in a trial, we could have gone through 100 different drugs by now and known definitively which ones worked or not. The disorder is global, and there aren’t enough tests right now to practice effective public health.  

Chaotic search for coronavirus treatments undermines efforts, says Angus

WASHINGTON POST - “It’s a cacophony—it’s not an orchestra. There’s no conductor,” said Pitt Med and HPM faculty's Derek Angus (BCHS '92), who is leading a covid-19 trial to test multiple therapies. “My heart aches over the complete chaos in the response.” The lack of coordination puts the world at risk of ending up with a raft of inconclusive and conflicting studies and little idea of what interventions work for the next wave of illness.  

Angus comments on first results from Gilead coronavirus drug

ASSOCIATED PRESS - A dozen patients had serious problems but it’s not clear whether they were from the drug or their disease. UPMC critical care chief and HPM faculty member Derek Angus (BCHS '92) said the recovery rate is good but “there is no way of knowing from this series if the antiviral drug was helpful.”  

Page 5 of 36First   Previous   1  2  3  4  [5]  6  7  8  9  10  Next   Last   

Search for an Article

Share Your News

Simply click to share news of your achievements—and those of classmates or colleagues. We’re eager to hear about and share stories of student, faculty, and alumni accomplishments. Email questions to phcomm@pitt.edu
or visit publichealth.pitt.edu/sharenews.

Share news

HPM Alumni Newsletters

Read our department newsletters:

The Department is transitioning to an online newsletter format. If you would like to continue to receive a paper copy of the newsletter or if you need to update your mailing or email address, please fill out this survey

And, view the latest HPM news online!

Find news by department

Use the "Search for an article" field above to filter news by keyword, or follow the links below to view by department: